33 results
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
28 Aug 23
Current report (foreign)
4:49pm
; and
established a written Code of Business Conduct and Ethics.
National Instrument 58-101 — Disclosure of Corporate Governance Practices (“NI 58 … remains current.
Ethical Business Conduct
The Corporation has adopted a Code of Business Conduct and Ethics (the “Code”) that applies to the directors
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
22 Aug 22
Current report (foreign)
11:39am
;
established a written Disclosure and Insider Trading Policy; and
established a written Code of Business Conduct and Ethics.
National Instrument 58 … and Ethics (the “Code”) that applies to the directors, officers and employees of the Corporation and its subsidiaries. Additionally, consultants and agents
SUPPL
MDNAF
Medicenna Therapeutics Corp.
10 Aug 22
Supplemental materials (foreign)
3:10pm
and the failure to demonstrate efficacy and safety;
the risks of delays and inability to complete clinical trials due to difficulties in securing ethics approvals
SUPPL
MDNAF
Medicenna Therapeutics Corp.
8 Aug 22
Supplemental materials (foreign)
8:40pm
to difficulties in securing ethics approvals and enrolling patients;
the risks associated with the Corporation’s inability to successfully develop
20-F
EX-15.2
r5qpk4670yegvn0g
22 Jun 22
Annual report (foreign)
5:04pm
20-F
2e9ivxqw70yx07sdsqi
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-15.1
by1v8ajloi hrb
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-11.1
nn50h9l
22 Jun 22
Annual report (foreign)
5:04pm
6-K
EX-99.1
htj3nwmh t0j8j
22 Jun 22
Current report (foreign)
8:00am
6-K
EX-99.3
lxzr7
22 Jun 22
Current report (foreign)
8:00am
6-K
EX-99.2
l02w3ne64vvvce9x
9 Feb 22
Interim condensed consolidated financial statements of
7:18am
6-K
EX-99.2
fje89 brys
12 Nov 21
Interim condensed consolidated financial statements of
7:15am
6-K
EX-99.1
1ai4vhaqr0d6
1 Sep 21
Current report (foreign)
8:00am
6-K
EX-99.2
xqbujs2x
13 Aug 21
Interim condensed consolidated financial statements of
7:10am
6-K
EX-99.5
ft2jx7hf0isjorjx
13 Aug 21
Interim condensed consolidated financial statements of
7:10am
6-K
EX-99.1
4f3rkdhir89t nztk
27 Jul 21
Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference
10:49am
6-K
EX-99.1
k5v6 2ukg
23 Jun 21
Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11
9:15am
40-F
c2o zrwngejbe4mn
28 May 21
Annual report (Canada)
12:12pm
40-F
EX-99.1
ljcrpc426iobv
28 May 21
Annual report (Canada)
12:12pm